Clinical applications of PET and PET/CT in pediatric malignancies

Expert Review of Anticancer Therapy

Volumn 10, Issue 5, 2010, Pages 755-768

  Kumar, Rakesh ^a   Shandal, Varun ^a   Shamim, Shamim Ahmed ^a   Halanaik, Dhanapathi ^a   Malhotra, Arun ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Conventional imaging; FDG; Pediatric malignancies; PET; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RINGER LACTATE SOLUTION; SODIUM CHLORIDE;

ANATOMY; BONE TUMOR; CANCER DIAGNOSIS; CANCER SIZE; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FIBROSARCOMA; FUNCTIONAL STATUS; GERM CELL TUMOR; GONAD TUMOR; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA; LIVER TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC RATE; METABOLIC REGULATION; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; REVIEW; RHABDOMYOSARCOMA; SEDATION; TREATMENT INDICATION; TREATMENT RESPONSE; ULTRASOUND; URINARY CATHETER; X RAY;

AGE FACTORS; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77952533409     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.12     Document Type: Review

References (67)

1. Stiller CA. Aetiology and epidemiology. In: Paediatric Oncology: Clinical Practice and Controversies. Plowman PN, Pinkerton CR (Eds). Chapman and Hall Medical, London, UK (1992).
2. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute, Bethesda, MD, USA (2007).
3. Kumar R, Dhanpathi H, Basu S, Rubello D, Fanti S, Alavi A. Oncologic PET tracers beyond ((18) F) FDG and the novel quantitative approaches in PET imaging. Q. J. Nucl. Med. Mol. Imaging 52, 50-65 (2008). An excellent review which describes PET radiopharmaceuticals other than FDG.
4. Barai S, Bandopadhayaya GP, Julka P et al. Evaluation of Tc99m-glucoheptonate for SPECT functional imaging of medulloblastoma. J. Clin. Neurosci. 12 (1), 36-38 (2005).
5. O'Tuama LA, Treves ST, Larar JN et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. J. Nucl. Med. 34, 1045-1051 (1993).
6. Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J. Neurosurg 69, 830-838 (1988).
7. Di Chiro G, Oldfield E, Wright DC et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR. Am. J. Roentgenol. 150, 189-197 (1988). (Pubitemid 18027033)
8. 18F] fluorodeoxyglucose positron emission tomography. Ann. Neurol. 29, 347-355 (1991).
9. Hoffman JM, Hanson MW, Friedman HS et al. FDG-PET in pediatric posterior fossa brain tumors. J. Comput. Assist. Tomogr. 16, 62-68 (1992).
10. Borgwardt L, Carstensen H, Schmiegelow K, Højgaard L. Increased FDG uptake in childhood CNS tumors is associated with tumor malignancy. Clin. Positron Imaging 3, 175 (2000).
11. Holthoff VA, Herholz K, Berthold F et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 72, 1394-1403 (1993).
12. 18F) fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery 55, 1280-1288 (2004). One of the best papers that evaluates the role of PET in medulloblastoma.
13. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S. Correlation of aminoacid uptake using methionine PET and histological classifications in various gliomas. Ann. Nucl Med. 19, 677-683 (2005).
14. O'Tuama LA, Phillips PC, Strauss LC et al. Two-phase (11C) L-methionine PET in childhood brain tumors. Pediatr. Neurol. 6, 163-170 (1990).
15. 11C-methionine in the paediatric brain tumors. Clin. Positron Imaging 3, 157 (2000).
16. Pirotte B, Levivier M, Morelli D et al. Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors. Childs Nerv. Syst. 21, 294-300 (2005).
17. Kaplan AM, Bandy DJ, Manwaring KH et al. Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. J. Neurosurg. 91, 797-803 (1999).
18. Pirotte B, Goldman S, Salzberg S et al. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr. Neurosurg 38, 146-155 (2003).
19. 11C) methionine-PET and MRI for imageguided surgical resection of brain tumors in children.
20. Pirotte B, Acerbi F, Lubansu A, Goldman S, Brotchi J, Levivier M. PET imaging in the surgical management of pediatric brain tumors. Childs Nerv. Syst. 23, 739-751 (2007).
21. Borgwardt L, Højgaard L, Carstensen H et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J. Clin. Oncol. 23, 3030-3037 (2005).
22. Schifter T, Hoffman JM, Hanson MW et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J. Comput. Assist. Tomogr. 17, 509-561 (1993).
23. Patronas NJ, Di Chiro G, Kufta C et al. Prediction of survival in glioma patients by means of positron emission tomography. J. Neurosurg. 62, 816-822 (1985).
24. 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J. Comput. Assist. Tomogr. 30, 689-694 (2006). Early paper on PET/CT in staging and follow-up of pediatric lymphoma.
25. Montravers F, McNamara D, Landman-Parker J et al. ((18) F) FDG in childhood lymphoma: clinical utility and impact on management. Eur. J. Nucl. Med. Mol. Imaging 29, 1155-1165 (2002).
26. 18F-FDG PET in children with lymphomas. Eur. J. Nucl. Med. Mol. Imaging 32, 31-38 (2005).
27. Amthauer H, Furth C, Denecke T et al. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up. Klin. Padiatr. 217, 327-333 (2005).
28. Hernandez-Pampaloni M, Takalkar A, Yu JQ, Zhuang H, Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr. Radiol. 36, 524-531 (2006).
29. Rhodes MM, Delbeke D, Whitlock JA et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J. Pediatr. Hematol. Oncol. 28, 300-306 (2006).
30. Hermann S, Wormanns D, Pixberg M et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 44, 1-7 (2005).
31. Rini JN, Núñez R, Nichols K et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr. Radiol. 35, 169-178 (2005).
32. Meany HJ, Gidvani VK, Minniti CP Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr. Blood Cancer 48, 399-402 (2007). Very good study in which authors describe PET scans in predicting relapse in pediatric Hodgkin's lymphoma.
33. Mody RJ, Bui C, Hutchinson RJ, Frey KA, Shulkin BL. Comparison of (18) F Fluorodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. Leuk. Lymphoma 48, 699-707 (2007).
34. Lopci E, Burnelli R, Ambrosini V et al. (18) F-FDG PET in pediatric lymphomas: a comparison with conventional imaging. Cancer Biother. Radiopharm. DOI:10.1089/cbr.2007.0519 (2008) (Epub ahead of print).
35. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J. Pediatr. Hematol. Oncol. 28, 711-714 (2006).
36. 18F-FDG PET in pediatric Hodgkin's lymphoma.
37. Furth C, Denecke T, Steffen I et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. J. Pediatr. Hematol. Oncol. 28, 501-512 (2006).
38. Völker T, Denecke T, Steffen I et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J. Clin. Oncol. 25, 5435-5341 (2007).
39. Tateishi U, Hosono A, Makimoto A et al. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas. J. Pediatr. Hematol. Oncol. 29, 608-612 (2007).
40. Klem ML, Grewal RK, Wexler LH, Schöder H, Meyers PA, Wolden SL. PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J. Pediatr. Hematol. Oncol. 29, 9-14 (2007).
41. Peng F, Rabkin G, Muzik O. Use of 2-deoxy-2-(F-18)-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study. Clin. Nucl. Med. 31, 394-397 (2006).
42. 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr. Blood Cancer 49, 901-905 (2007).
43. Lenzo NP, Shulkin B, Castle VP et al. FDG-PET in childhood soft tissue sarcoma. J. Nucl. Med. 41 (5 Suppl.), 96P (2000).
44. Kumar R, Chauhan A, Vellimana AK, Chawla M. Role of PET/PET/CT in the management of sarcomas. Expert Rev. Anticancer Ther. 6 (8), 1241-1250 (2006) Excellent review of published studies of PET and PET/CT in the management of sarcomas.
45. Shulkin BL, Mitchell DS, Ungar DR et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology 194, 495-500 (1995).
46. Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin. Nucl. Med. 25, 874-881 (2000).
47. Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D- glucose positron emission tomography. Cancer 94, 3277-3284 (2002).
48. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol. 23, 8828-8834 (2005).
49. Jadvar H, Alavi A, Mavi A, Shulkin BL. PET in pediatric diseases. Radiol. Clin. North Am. 43, 135-152 (2005).
50. Brisse H, Ollivier L, Edeline V et al. Imaging of malignant tumors of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr. Radiol. 34, 595-605 (2004).
51. Györke T, Zajic T, Lange A et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumors. Nucl. Med. Commun. 27, 17-24 (2006).
52. Huang TL, Liu RS, Chen TH, Chen WY, Hsu HC, Hsu YC. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma. J. Chin. Med. Assoc. 69, 372-376 (2006). Very good study comparing PET with tumor necrosis for assessment of tumor response.
53. Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the US. Cancer 78, 532-541 (1996).
54. Brodeur GM, Maris JM. Neuroblastoma: Principles and Practice of Pediatric Oncology (4th Edition). Lippincott-Raven Publishers, PA, USA 895-937 (2001).
55. 123I-MIBG SPECT/CT. J. Nucl. Med. 47, 1635-1642 (2006).
56. Shulkin BL, Hutchinson RJ, Castle V P, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy- D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199, 743-750 (1996).
57. Shulkin BL, Wieland DM, Baro ME et al. PET hydroxyephedrine imaging of neuroblastoma. J. Nucl. Med. 37, 16-21 (1996).
58. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J. Clin. Oncol. 19, 3397-3405 (2001).
59. 18F-FDG PET in neuroblastoma.
60. Wong KK, Lan LC, Lin SC, Tam PK. The use of positron emission tomography in detecting hepatoblastoma recurrence - a cautionary tale. J. Pediatr. Surg. 39, 1779-1781 (2004).
61. Mody RJ, Pohlen JA, Malde S, Strouse PJ, Shulkin BL. FDG PET for the study of primary hepatic malignancies in children. Pediatr. Blood Cancer 47, 51-55 (2006).
62. 18F) fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38, 6-8 (2001).
63. 18F]- DOPA positron emission tomography. Diabetes 55, 13-18 (2006). Excellent research work on F-DOPA PET in diagnosis of focal hyperinsulinism of infancy.
64. Bombardieri E, Aktolun C, Baum RP et al. FDG-PET: procedure guidelines for tumor imaging. Eur. J. Nucl. Med. Mol. Imaging 30, BP115-BPI24 (2003).
65. 11C-methionine positron emission tomography. Cancer 95, 1376-1386 (2002).
66. Kwon JW, Kim IO, Cheon JE et al. Paediatric brain-stem gliomas: MRI, FDG-PET and histological grading correlation. Pediatr. Radiol. 36, 959-964 (2006).
67. Gururangan S, McLaughlin CA, Brashears J et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J. Neurooncol. 77, 207-212 (2006).